The CLIP-Substituted Invariant Chain Efficiently Targets an Antigenic Peptide to HLA Class II Pathway in L Cells

Shinji Fujii, Satoru Senju, Yu-Zhen Chen, Masayuki Ando, Sho Matsushita, and Yasuharu Nishimura

ABSTRACT: The presentation of antigenic peptides by major histocompatibility complex (MHC) class II to CD4+ T cells is crucial to initiate immune responses. We developed a new system for delivery of an antigenic peptide to the MHC class II pathway, using the invariant chain (Ii). We designed a mutated human p33-form Ii, CLIP-substituted Ii, in which streptococcal M12p55-68 (RDLEQAYNELSGEA) was substituted for CLIP (class II associated invariant chain peptide). We examined the peptide presenting function of this construct, in comparison with the previously reported C-terminal fused Ii, in which a cathepsin cleavage site and M12p54-68 was ligated to the C-terminus of Ii. Mouse L cell transfectants expressing either of these two mutated Ii along with HLA-DR4 could process and present M12p55-68 to the peptide specific and DR4-restricted CD4+ T cell clone. CLIP-substituted Ii was much more efficient in antigen presentation than was the C-terminal fused Ii. Similar to the wild-type Ii, the CLIP-substituted Ii was associated intracellularly with DR4 molecules. These results indicate that the peptide substituted for CLIP of Ii p33 bound to the groove of DR molecules in the same manner as CLIP and it was preferentially presented to the CD4+ T cell clone in the absence of HLA-DM molecules. This system may prove useful for immunotherapy with DNA vaccines or for construction of an antigen presenting cell library with diverse peptides. Human Immunology 59, 607–614 (1998). © American Society for Histocompatibility and Immunogenetics, 1998. Published by Elsevier Science Inc.

ABBREVIATIONS
- APC: antigen presenting cell
- CLIP: class II-associated invariant chain peptide
- HLA: human leukocyte antigen
- Ii: invariant chain
- mAb: monoclonal antibody
- MHC: major histocompatibility complex

INTRODUCTION
The recognition of antigenic peptides in the context of major histocompatibility complex (MHC) class II by CD4+ T cells is crucial to initiate immune responses. Establishment of a system for efficient delivery of antigenic peptides to the MHC class II pathway is an approach which will enhance immune responses of CD4+ T cells and should be useful for development of a potent vaccine. For this purpose, a system is needed to deliver a given specific antigen onto MHC class II molecules and a strategy of introducing gene encoding antigenic peptide to antigen presenting cells (APC) is useful in many respects. However, except for membrane or secretory proteins, many proteins endogenously synthesized by gene introduction as well as viral infection are degraded into peptide fragments by proteasomes in cytoplasm, which are transported into the lumen of the endoplasmic reticulum by the transport associated with antigen processing (TAP). The peptides then bind to MHC class I molecules and are presented to CD8+ T cell [1]. The use
of antigenic molecules with targeting signals to endosomes is a pertinent strategy for antigen presentation to CD4+ T cell via class II pathway by gene introduction. Several systems have been reported to use various molecules with targeting signals, including cathepsin D [2], lysosomal-associated membrane protein LAMP-1 [3], and the invariant chain [4–6].

The invariant chain is type II integral membrane glycoproteins. The p33 and p35 forms of Ii, both encoded by eight exons, differ by 16 N-terminal residues as a result of alternative translational initiation [7]. The p41 Ii, encoded by nine exons, is generated by alternative splicing of a common pre-mRNA. Theoretically, an additional p43 form could be expected [8], but is not yet unequivocally detected in immunoprecipitates from human cells. Among Ii isoforms, the p33 form is predominant in the human Ii chain. Ii has two known important functions with regard to antigen presentation by MHC class II molecules: First, Ii associates with newly synthesized MHC class II α and β dimers in the endoplasmic reticulum to form a complex and directly prevents peptides in the endoplasmic reticulum from binding to MHC class II molecules, using a domain termed class II-associate Ii peptide (CLIP) that occupies the peptide-binding groove of class II αβ dimers [9–11]. This αβ-Ii complex is composed of one Ii trimer and three αβ dimers [12] and transported via the Golgi apparatus to the endosomal pathway by the targeting signal, dileucine motif, in the cytoplasmic domain of Ii [13, 14]. In this pathway, Ii is proteolytically degraded and the αβ-CLIP complex is generated. In specialized endocytic organelles enriched in MHC class II molecules and designated MHC class II compartments (MIIC) [15, 16] or class II vesicles (CIIV) [17], HLA-DM catalyzes the dissociation of CLIP from class II αβ dimer and binding of other peptides [18, 19].

Thus Ii contains not only the targeting signal to the endosomal pathway but also CLIP bound to the peptide-binding groove of MHC class II molecules. We reasoned that a CLIP-substituted Ii vector, encoding the Ii chain containing an antigenic peptide replacing CLIP, might efficiently load antigenic peptides on MHC class II molecules. We tested this thesis in comparison with the C-terminal fused Ii [5] and found that CLIP-substituted Ii is effective in targeting peptides to MHC class II-mediated antigen presentation pathway.

MATERIALS AND METHODS

Cells and Antibodies

The CD4+ αβ T cell clone YN5-32 was established from a donor heterozygous for HLA-DRB1*0401 and HLA-DRB1*0406, by stimulating peripheral blood mononuclear cells with the peptide M12p54-68 (NRDLEGAY NELSGEA), which corresponds to amino acid residues 54 to 68 of the M protein derived from a group A β hemolytic streptococcus, as described elsewhere [20]. The L cell transfectant LDR4 (B18D7) expressing the DRA gene plus DRB1*0406 gene [21] was distributed in the 11th International Histocompatibility Workshop [22]. For flow cytometry, the Fluorescein Isothiocyanate (FITC) conjugated mouse anti-human invariant chain mAb M-B741 and anti-HLA-DR mAb L243 were purchased from PharMingen (San Diego, CA) and Becton Dickinson Immunocytometry Systems (San Jose, CA), respectively. The mouse anti-human CLIP mAb CerCLIP.1 [23] was kindly provided by P. Cresswell (Yale University). FITC labeled goat anti mouse IgG+IgM was purchased from BIOSOURCE (Camilo, CA).

Plasmid DNA Constructs

The cDNA encoding human p33 Ii (American Type Culture Collection, Rockville, MD) was subcloned into the expression vector pYN containing the SRI promoter [24]. The vector pCI was prepared, in which the DNA sequence encoding the CLIP region (89SKMRMATPL LMQLALPM89) of Ii can be replaced by various sequences encoding antigenic peptides. The PinA I and Sac I sites were newly created by site-directed mutagenesis with mutagenic primers 5′-GCC TCC CAA ACC GGT GAG CAA GAT TTG GAA CAA GCG TAT AAT 3′ and 5′-CCA TGG GAG CT 3′, using Transformer™ Site-Directed Mutagenesis Kits (CLONTECH, Palo Alto, CA). To generate pCIM, encoding mutant Ii containing M12p55-68 replacing CLIP, oligonucleotides 5′-CGT GAC TTG CAA GAA CCG TAT ATG GAG CTT AGC GGA GAA GCA CCC ATG GGA GCA CCA CCC ATG GCT TCT CCG CTA AGC TCA TTA TAC GCT TGT GCC TCC AGG AGG AAG TCA CGC A-3′ were annealed and subsequently ligated to pCI digested with the PinA I and Sac I. The C-terminal fused Ii vector pFIM, as reported [5], was constructed by inserting two dsDNA fragments in tandem after annealing the oligonucleotides 5′-GAT TTC TTA TTA GAA GAA AAA AAA TCC GGA AAT CGT GAT-3′ and 5′-CTA GAT CAC GAT TTC CGG ATT TTT TTT TTT CTA AGA AAT TT-3′, 5′-GTA GAA CAA CCA CCT GAT TAT AAT GAG CTT AGC GGA GAA GCA TGA GAT-3′ and 5′-CTA GAT CTC ATG CTT CTC CGG TAA GCT CAT TAT AAC CTT GTT-3′ at the Xcm I site. These dsDNA fragments encode the cathepsin D cleavage site (FLEEKKSG) followed by M12p54-68 (NRDLEGAY NELSGEA) at the C-terminus of Ii.

Flow Cytometry

Cell surface staining for flow cytometric analysis was carried out as described elsewhere [20]. For intracellular staining, The cells were fixed in Dulbecco’s Modified
Eagle Medium (Gibco, Grand Island, NY) containing 1% paraformaldehyde (Wako, Osaka, Japan) for 10 min at room temperature and permeabilized by twice washing with Dulbecco’s Modified Eagle Medium containing 0.1% saponin (SIGMA, St. Louis, MO) and 1% fetal calf serum. After incubation for 30 min at room temperature with the indicated mAb in the presence of 0.1% saponin and two additional washes, the cells were analyzed on FACScan (Becton Dickinson, Mountain View, CA).

Metabolic Labeling and Immunoprecipitation
Cells (1 × 10^6) grown in 6 well plate (Falcon, Becton Dickinson, Lincoln Park, NJ) were starved for 30 min in methionine- and cysteine-free Dulbecco’s Modified Eagle Medium (Gibco) containing 2% fetal calf serum. [35S] methionine/cysteine (ICN, Irvine, CA) was added to a final concentration of 3.7 MBq/ml, and the cells were incubated at 37°C for 2 h. After removal of the medium the cells were washed twice with phosphate buffered saline then harvested from the wells by adding 1 ml ice-cold lysis-buffer [phosphate buffered saline containing 1% Nonidet P-40 , 1 mM PMSF (SIGMA), and 1 μg/ml pepstatin (SIGMA)]. After rocking the lysate at 4°C for 10 min the samples were centrifuged for 10 min at 15,000 g at 4°C to remove nuclei. For immunoprecipitation, 60 μl of a slurry of protein A-Sepharose beads preabsorbed with HU-4 was added to the lysates followed by gentle rotation for 1 h at 4°C. The beads were washed four times with phosphate buffered saline containing 1% Nonident P-40 and twice with phosphate buffered saline. The beads were then boiled in sample buffer for 4 min and supernatants were applied to SDS-PAGE. After electrophoresis, the gel was fixed, vacuum dried, and analyzed using radioautography or a fluorescence imaging system (FLA2000, Fuji Film, Tokyo, Japan).

T Cell Proliferation Assay
Antigen-specific proliferation of the T cell clone was investigated, as described [25]. L cell transfectants were used as APC, and peptide pulse of L cell transfectants was done as follows: L cell transfectants were treated with 20 μg/ml of mitomycin C (SIGMA) as described [26], and 3.5 × 10^4 cells/well were incubated with Dulbecco’s Modified Eagle Medium supplemented with 10% fetal calf serum and the indicated peptide in a 96-well plate for 16 h, followed by two washings with RPMI 1640. The T cell clone (3 × 10^6) was cultured with APC for 72 h then was pulsed with 1 μCi/well of [3H] thymidine for the last 16 h. The cells were then harvested and the incorporated radioactivity was measured by liquid scintillation counting.

RESULTS

Generation of Mutated Ii Genes
As shown in Fig. 1, the CLIP-substituted Ii vector (pCIM) was created by inserting the sequence encoding the streptococcal M protein-derived peptide M12p55-68 (RDLEGAYNELSGEA), the epitope of HLA-DR4 (DRA1 DRB1*0406) restricted CD4+ T cell clone YN5-32, into the CLIP region of pCI. The putative MHC first anchor residue for this epitope was assigned to be L57 [20]. On the other hand, CLIP was shown by X-ray crystal structure analysis to be bound to HLA-DR3 molecules in a manner practically identical to that in which antigenic peptides are bound in the groove of the HLA-DR molecule. It is assumed that the first DR-anchor residue of CLIP is M91 [11]. To make the peptide-DR conforma-
tion proper for recognition by YN5-32, we designed the CLIP-substituted Ii construct to locate L57 of M12p55-68 at position M91 in wild-type Ii. The construct of the C-terminal fused Ii vector (pFIM) contains a cathepsin D cleavage site (FLEEKKSG) followed by the antigenic peptide M12p54-68 in the COOH-terminus, a strategy reported by Nakano et al. [5].

Expression of Cell Surface HLA-DR and CLIP, and of Intracellular Ii in the Transfected L Cells

Expression of the Ii was detected by intracellular staining of permeabilized cells with the M-B741 mAb. This mAb previously reported to recognize the lumenal domain of human Ii [27] detected the CLIP-substituted Ii as well as wild-type and C-terminal fused Ii, thereby indicating that this mAb recognizes Ii, irrespective of the sequence at the portion of CLIP. As shown in Fig. 2, the four L cell transfecants expressing comparable levels of HLA-DR and Ii were used for subsequent functional assay. The CerCLIP.1 mAb, specific to CLIP in association with
class II molecules, stained wild-type Ii- and C-terminal fused Ii-, but not CLIP-substituted Ii-transfected L cells.

Association of HLA-DR with the Invariant Chain
It has been reported that Ii-trimer composes a nonameric complex with MHC class II α and β chains in the endoplasmic reticulum and functions as a molecular chaperone to target them to endosomes [9]. We asked if the CLIP-substituted Ii was also associated intracellularly with HLA-DR molecules. LDR4, wild-type Ii-LDR4 (LDR4-Ii), and CLIP-substituted Ii-LDR4 (LDR4-CIM) were metabolically labeled with [35S] methionine/cysteine, lysed in mild detergent condition, and precipitated with the anti-HLA-DR mAb (Fig. 3). Both wild-type and CLIP-substituted Ii were coprecipitated with DR, albeit the amount of CLIP-substituted Ii coprecipitated with DR was smaller than that of wild-type Ii, suggesting that CLIP-substituted Ii is not associated with DR as stably as is the wild-type Ii or degraded faster than wild-type Ii. Precipitation with the anti-Ii mAb also indicated the association of CLIP-substituted Ii with HLA-DR and immunoprecipitates was not detected in LDR4 (data not shown).

Stimulation of the Antigen Specific CD4+ T Cell Clone
To determine if these mutated Ii could load the antigenic peptide on HLA-DR molecules, we tested the proliferative response of the T cell clone YN5-32. CLIP-substituted Ii-LDR4 (LDR4-CIM) and C-terminal fused Ii-LDR4 (LDR4-FIM), but not wild-type Ii-LDR4 (LDR4-Ii) and LDR4 stimulated the proliferative response of YN5-32 in the absence of antigenic peptide. T cell proliferation stimulated by LDR4-CIM was approximately twofold over that induced by LDR4-FIM (Fig. 4). To investigate the correlation between expression level of Ii and efficiency of antigen presentation, CLIP-substituted Ii-LDR4 with two different expression levels of Ii, high expresser (LDR4-CIMhi) and low expresser (LDR4-CIMlo), were prepared (Fig. 5A). These two transfectants expressed almost the same amount of DR molecules on the cell surface (data not shown). We tested proliferative responses of YN5-32 induced in the presence of transfectants prepulsed with several different concentrations of M12p54-68 peptide. As shown in Fig. 5B, at the range of peptide concentrations from 0 to 10^{-2} μM, proliferative response to either LDR4-CIMhi or LDR4-CIMlo constantly exceeded that to LDR4-FIM.

FIGURE 3  Association of HLA-DR with Ii. L cell transfectants were labeled for 2 h with [35S] methionine/cysteine. Cell lysates were immunoprecipitated with anti-DR mAb HU-4. Samples were analyzed by 11% SDS-PAGE under reduced conditions. The migration positions for Ii p33, the DR α and β chains are indicated. Names of the transfectants are given at the top.

FIGURE 4  Stimulation of the antigen specific T cell clone by L cell transfectants expressing mutated Ii-genes. T cell clone YN5-32 was cultured in the presence of the indicated L cell transfectants as APCs without the antigenic peptide, and the proliferative response was measured by[^1H] thymidine incorporation. Results are expressed as means of triplicate determinations ± standard error.[^1H] thymidine incorporation into L cell transfectants alone or T cell alone did not exceed 100 cpm.
Moreover, proliferative responses to LDR4-CIM<sup>hi</sup> reached the approximate plateau level in the absence of antigenic peptide. On the other hand, proliferative responses of YN5-32 to LDR4-CIM<sup>lo</sup> and LDR4-FIM increased in a peptide dose-dependent manner in the presence of $10^{-1}$–$10^{-5}$ μM peptide.

**DISCUSSION**

We obtained evidence that the CLIP-substituted Ii vector is efficient in loading an antigenic peptide onto MHC class II and stimulating CD<sub>4</sub><sup>+</sup> T cells. Almost the same strategy was used by other investigators to present an influenza haemagglutinin-derived peptide to an HLA-DR1 restricted CD<sub>4</sub><sup>+</sup> T cell clone [6]. Our data show the effectiveness of this strategy for a different antigenic peptide and different allelic product of DR, in comparison with C-terminal fused Ii vector, and in addition, assembly of mutated Ii with DR, suggesting that the inserted antigenic peptide is loaded on the groove of MHC class II in a same way as CLIP, in case of wild-type Ii. The peptide loading process, similar to natural association of CLIP with DR, may provide a higher efficiency when using this vector than that of C-terminal fused Ii vector, as shown in the current study. The CLIP-substituted Ii vector is considered to target the peptide not only to endosomes but also to the groove of MHC-class II. On the other hand, in case of the C-terminal fused Ii vector, the antigenic peptide cleaved out from C-terminus of Ii should locate in the groove of MHC class II and replace CLIP to be presented to CD<sub>4</sub><sup>+</sup> T cells. Because L cells do not express H-2M molecules [28], the antigenic peptide substituted for CLIP may not be dissociated from DR molecules in LDR4-CIM. On the contrary, replacement of CLIP with an antigenic peptide may not be efficient in LDR4-FIM. This may cause a more acceptable antigen presenting capacity of LDR4-CIM, as compared with LDR4-FIM.

We also found that efficiency of antigen presentation depends on the expression level of CLIP-substituted Ii. The proliferative response of the T cell clone to LDR4-CIM<sup>hi</sup> reached the approximate plateau level in the absence of antigenic peptide, indicating that LDR4-CIM<sup>hi</sup> expressed a large number of DR-antigenic peptide complexes on the cell surface sufficient to stimulate full activation of the T cell clone. On the other hand, the proliferative response of YN5-32 to LDR4-CIM<sup>lo</sup> increased in a peptide dose-dependent manner. This means that density of the DR-antigenic peptide complexes expressed on these two transfecants did not reach a level sufficient to stimulate full activation of T cells and that empty DR4 molecules or DR4 molecules complexed with L cell-derived peptides presented exogenously added antigenic peptides to T cells.
The anti-CLIP mAb CerCLIP.1 recognizes CLIP in association with HLA class II molecules [23]. Staining with CerCLIP.1 showed that LDR4-Ii and LDR4-FIM expressed class II αβ-CLIP complex similar to T2, a human cell line deleted in HLA-linked genes including HLA-DM [29], but not LDR4-CIM. This observation supports an notion that CerCLIP.1 recognizes CLIP residues 89-102 in the context of HLA-DR. Alternatively it is possible that the mAb cannot recognize an epitope on CLIP 81-89 in LDR4-CIM because of an alteration in conformation by substitution at residues 89-102.

Modulation of immune responses by stimulating or antagonizing specific T cell populations in vivo may be one avenue to use when designing treatment of subjects with allergic or autoimmune diseases or even for anticancer immunotherapy. It would be essential to identify peptides which can stimulate pathogenic T cells. We are using pCI, our CLIP-substituted Ii vector, to establish an expression library system for use in searching epitopes for specific CD4+ T cells. A different type of vector to load an antigenic peptide onto MHC class II has been reported by Ignatowicz et al. [30], in which the peptide was covalently linked to the N-terminus of the β chain of MHC class II. pCI seems to be more useful than the β chain-linked vector in that, once established, the pCI library can be applied to various allelic products and classes of MHC class II molecules. Although the epitope identified by this strategy is not necessarily the natural ligand of the T cells, it is possible that the epitope works as well as or even more efficiently than natural epitopes.

pCI may also prove useful to present specific epitope to CD4+ T cells in vivo, as a DNA vaccine. Infusion of synthetic peptides or peptide-pulsed antigen presenting cells may also be used for that purpose. However, DNA transfer of a pCI encoding specific peptide is thought to be more efficient and longer lasting, because the epitope is continuously produced and is loaded onto MHC class II in vivo.

ACKNOWLEDGMENTS
This present work was supported by Grants-in Aid 08282104, 08557027, and 09470097 from the Ministry of Education, Science, Sports and Culture, Japan; a Research Grant for Intractable Diseases from the Ministry of Health and Welfare, Japan; Japan Rheumatism Foundation, Mochida Memorial Foundation, and The Naito Foundation. We thank Dr. P. Creswell (Yale university) for anti-CLIP mAb CerCLIP.1, Dr. Y. Nakabeppu (Kyushu university) for pYN3214-lacZ, and M. Ohara for helpful comments.

ADDENDUM
After this work was completed a similar approach was presented by Malcherek G et al., Eur J Immunol 28: 1524, 1998.

REFERENCES


